Acute Myeloid Leukemia | Tumor

CURE’s acute myeloid leukemia page features the latest cancer news and updates on acute myeloid leukemia. Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in acute myeloid leukemia.

FDA Approves Tibsovo for Frontline IDH1-Mutant Acute Myeloid Leukemia

May 2nd 2019, 11:12pm

Article

The FDA has approved a supplemental new drug application for Tibsovo as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia who are 75 years and older or are ineligible to receive intensive chemotherapy.

FDA Grants Priority Review to Tibsovo for Acute Myeloid Leukemia Subgroup

February 20th 2019, 7:53pm

Article

The Food and Drug Administration granted a priority review to Tibsovo (ivosidenib) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.

FDA Approves Xospata and Companion Diagnostic Test for Leukemia Treatment

November 29th 2018, 12:53am

Article

The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.

Striking a Match for Stem Cell Transplants

September 14th 2018, 6:31pm

Article

Techniques open a field of opportunity for stem cell transplant recipients.

FDA Approves Nivestym for Acute Myeloid Leukemia and More

July 23rd 2018, 4:49pm

Article

The Food and Drug Administration approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for five eligible indications.

FDA Approves Tibsovo, First IDH1 Inhibitor for Acute Myeloid Leukemia

July 20th 2018, 8:51pm

Article

Today's approval of Tibsovo, along with the diagnostic tool to determine who should get it, brings a new type of treatment for patients with acute myeloid leukemia.

Genetic Mutation Can Predict Acute Myeloid Leukemia Risk a Decade Before Diagnosis

July 17th 2018, 8:23pm

Article

While there are known risk factors of developing acute myeloid leukemia (AML) – such as a myelodysplastic syndrome diagnosis and receiving chemotherapy and radiotherapy – a diagnosis can still stun and individual. But researchers at Weill Cornell Medicine and New York-Presbyterian recently discovered a genomic pre-malignant biomarker of the disease that can identify people who are at a greater risk for AML.

Novel Drug Granted Priority Review for Acute Myeloid Leukemia Treatment

June 27th 2018, 9:11pm

Article

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.

FDA Grants Gilteritinib a Priority Review for Acute Myeloid Leukemia Treatment

May 29th 2018, 7:42pm

Article

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML), according to Astellas Pharma, the manufacturer of the FLT3 inhibitor.

On Jackie Robinson and Bone Marrow Transplants

May 18th 2018, 4:09am

Article

“A life is not important except in the impact it has on other lives.”